Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2

Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma

(2014) Ami V. Desai et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Anti-GD2 strategy in the treatment of neuroblastoma

(2014) R.K. Yang et al.   DRUGS OF THE FUTURE

Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHO

(2014) Nikolai Siebert et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD2 Antibody

(2014) Nikolai Siebert et al.   PLoS One

Vaccination with anti-idiotype antibody ganglidiomab mediates a GD2-specific anti-neuroblastoma immune response

(2013) Holger N. Lode et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab

(2013) Nikolai Siebert et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients

(2013) Ruth Ladenstein et al.   mAbs

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

(2010) Alice L. Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

(2009) M. A. Cheever et al.   CLINICAL CANCER RESEARCH